ICON Public (NASDAQ:ICLR) Releases FY 2024 Earnings Guidance

ICON Public (NASDAQ:ICLR) issued an update on its FY 2024 earnings guidance on Saturday morning. The company provided earnings per share (EPS) guidance of 15.000-15.200 for the period, compared to the consensus estimate of 15.060. The company issued revenue guidance of $8.5 billion-$8.6 billion, compared to the consensus revenue estimate of $8.6 billion.

ICON Public Price Performance

ICLR stock traded up $10.36 on Friday, reaching $323.46. 908,602 shares of the company’s stock were exchanged, compared to its average volume of 788,375. The stock has a fifty day moving average of $322.17 and a 200-day moving average of $308.87. ICON Public has a twelve month low of $221.20 and a twelve month high of $347.72. The firm has a market cap of $26.69 billion, a PE ratio of 39.35, a P/E/G ratio of 1.44 and a beta of 1.23. The company has a quick ratio of 1.21, a current ratio of 1.31 and a debt-to-equity ratio of 0.36.

ICON Public (NASDAQ:ICLR) last released its earnings results on Wednesday, July 24th. The medical research company reported $3.75 EPS for the quarter, beating the consensus estimate of $3.68 by $0.07. The firm had revenue of $2.10 billion during the quarter, compared to analyst estimates of $2.14 billion. ICON Public had a return on equity of 12.06% and a net margin of 8.57%. The business’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.96 earnings per share. As a group, equities analysts predict that ICON Public will post 14.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ICLR shares. TD Cowen upped their price target on ICON Public from $349.00 to $373.00 and gave the stock a buy rating in a research note on Friday, May 31st. The Goldman Sachs Group initiated coverage on ICON Public in a research note on Thursday, June 6th. They issued a buy rating and a $370.00 target price for the company. Mizuho reiterated a buy rating and issued a $346.00 target price on shares of ICON Public in a research note on Thursday, April 4th. Robert W. Baird increased their target price on ICON Public from $367.00 to $376.00 and gave the company an outperform rating in a research note on Monday, July 8th. Finally, William Blair reiterated an outperform rating on shares of ICON Public in a research note on Friday, May 31st. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus price target of $352.56.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.